Based on mRNA gene expression levels, four basic molecular subtypes (luminal A, luminal B, HER2-enriched, and basal-like) can be distinguished among breast cancers, which allows for the implementation of new treatment strategies and patient stratifications that impact the management of breast cancer patients [1]. The gene discussed is ERBB2; the disease is breast carcinoma.